海普瑞(002399.SZ):以H股募集資金1.05億美元以逐層增資方式向全資子公司香港天道增資
格隆匯12月10日丨海普瑞(002399.SZ)公佈,經公司於2021年12月10日召開的第五屆董事會第十五次會議審議通過,公司決定使用H股募集資金1.05億美元以逐層增資的方式向全資子公司天道醫藥(香港)有限公司(以下簡稱“香港天道”)增資,用於歐盟及其他全球市場拓展銷售及營銷網絡以及基礎設施的建設。
具體增資路徑為海普瑞向其全資子公司深圳市多普樂實業發展有限公司(以下簡稱“多普樂”)增資,多普樂向其全資子公司深圳市天道醫藥有限公司(簡稱“深圳天道”)增資,深圳天道向其全資子公司香港天道增資。本次逐層增資後,多普樂、深圳天道、香港天道仍為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.